Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
182
resultados
Última actualización
16/01/2026 [07:23:00]
Resultados 50 a 75 de 182
Resumen de: WO2024130444A1
The present application provides compositions and methods of use for inhibiting DUPD1 activity or by reducing or eliminating expression of DUPD1 in order to treat and/or prevent inflammatory bowel disease, including Crohn's disease and ulcerative colitis, colitis- associated colon cancer, or a metabolic disorder, such as obesity or an obesity-associated metabolic disorder, or for glucose regulation in a subject. The present application further relates to the identification of compounds that are useful in treating and/or preventing inflammatory bowel disease, colitis-associated colon cancer, or a metabolic disorder, or for glucose regulation.
Resumen de: CN120831477A
The invention discloses a novel target of PPP2R1A as an anti-inflammatory therapeutic drug and application of the novel target, it is found for the first time that knock-down of PPP2R1A can significantly inhibit expression of an anti-inflammatory active compound PB in NF-kB, TNF-alpha and IL-1beta inflammatory factors in human colon tumor cells, and at present, the relationship between PPP2R1A protein and inflammation has not been researched. The invention provides a novel drug target for treatment of inflammatory diseases in the field, provides a practical and effective screening method for discovery of inflammation treatment leading drugs, provides a scientific basis for clinical treatment of ulcerative colitis, and has a good application prospect in the aspect of anti-inflammation.
Resumen de: WO2025218823A2
Disclosed in the present invention are a joint detection kit for detecting intestinal polyp factors, and a preparation method therefor, a detection method therefor and the use thereof. The joint detection kit at least comprises a plurality of test strips for detecting the following indicators: M2-pyruvate kinase, matrix metalloproteinase 9, myeloperoxidase, glutathione S-transferase Pi, cytidine deaminase, retinol binding protein 4, serine protease inhibitor F2, calprotectin and fecal occult blood. Conjugate pads of each reagent strip are coated with detection antibody-colloidal gold conjugates. Detection lines of the reagent strip are coated with specific capture antibodies, and the specific capture antibodies on each test strip are different. The joint detection performed by the joint detection kit of the present invention can effectively improve the sensitivity and specificity of the detection on intestinal polyps. The detection time is merely 15 min, with the detection rate of more than 91%. Therefore, the accuracy on the detection and diagnosis of colorectal cancer caused by intestinal polyps is improved.
Resumen de: CN120820665A
The invention discloses a biomarker for identifying superior mesenteric artery dissection related intestinal dysfunction. The biomarker is lysophospholipid. By means of the biomarker, a patient with intestinal dysfunction caused by SISMAD can be recognized in an early stage, operation intervention (mainly stent implantation) can be conducted in time, and malignant consequences such as intestinal necrosis, large-area intestinal resection, short bowel syndrome and infection death are avoided.
Resumen de: CN120818614A
The invention discloses a microbial marker for treating Crohn's disease based on coprophilous fungus transplantation and a screening method of the microbial marker. The microbial marker comprises the following components: Dialister insight, Roseburia intestinae, Parabacteroides verdeae, Bacteroides caccae, Blauria obeum, Bacteroides intestinae, Paraprevotella, and a combination of the Bacteroides cactinae, and further comprises the following components in parts by weight: 1, 1, 2, 3, 4, 5, 6, 7, 7, 8, 8, 8, 9, 10, 12, 13, 13, 13, 14, 16, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17 According to the invention, through metagenome sequencing and a machine learning algorithm, the key microbial marker which is significantly related to the symptom improvement of the Crohn's disease in the coprophilous fungus transplantation treatment process is screened out, and a scientific basis and a standardized scheme are provided for coprophilous fungus transplantation treatment of the Crohn's disease.
Resumen de: CN120796172A
The invention relates to the technical field of bioengineering, and discloses a construction method of an inflammatory bowel disease model, which comprises the following steps: constructing an inflammatory intestinal barrier by using intestinal cells derived from an inflammatory bowel disease patient; and S20, adding a stimulation solution containing immune cells and/or immune cell secretions into the inflammatory intestinal barrier, and carrying out co-culture to obtain the inflammatory bowel disease model. An inflammatory intestinal barrier constructed by using intestinal cells derived from an inflammatory bowel disease patient and adding immune components can retain IBD disease-related gene and cell shape feature expression characteristics, so that the model is closer to the pathological condition in the body of the patient; and moreover, the actual in-vivo pathological injury progress is better simulated, the bionic property of the model is improved, the injury of unbalanced immune cells to the intestinal tract in IBD pathology is reproduced, and potential drug targets can be found and verified. The invention further discloses an inflammatory bowel disease model and application thereof.
Resumen de: CN120789208A
The invention belongs to the technical field of traditional Chinese medicines, and relates to a traditional Chinese medicine composition for treating ulcerative colitis as well as a preparation method and application thereof. The invention discloses a traditional Chinese medicine composition for treating ulcerative colitis. The traditional Chinese medicine composition comprises the following components in parts by weight: 20-60 parts of codonopsis pilosula, 10-50 parts of roasted rhizoma atractylodis macrocephalae, 10-50 parts of roasted radix aucklandiae, 10-50 parts of parched white peony root, 10-50 parts of rhizoma cimicifugae, 10-50 parts of bran-fried Chinese yam, 10-50 parts of myristica fragrans, 20-40 parts of vinegar smoked plum, 10-30 parts of fried fructus chebulae, 10-30 parts of baked ginger and 5-45 parts of honey-fried licorice root. According to the traditional Chinese medicine composition provided by the invention, the level of a proinflammatory marker is remarkably reduced, the balance of M1/M2 macrophages in colon tissues is regulated, the damage of oxidative stress to the colon mucosal barrier can be effectively reversed, and the expression of a PI3K/AKT/mTOR signal channel and HIF-1alpha is regulated, so that the curative effects of relieving inflammatory response and accelerating repair are achieved.
Resumen de: US2025319052A1
This present invention relates to the use of eicosapentaenoic acid (EPA) for the treatment of ulcerative colitis (UC), and more particularly, the use of highly purified eicosapentaenoic acid as free fatty acids (EPA-FFA) having a purity of at least 95% for reducing inflammation in a subject suffering from ulcerative colitis and wherein the levels of IL-10 and SOCS3 are increased and the microbiome of the intestinal mucosal tissue is favorably modulated.
Resumen de: US2025321218A1
The present disclosure provides methods of selecting a treatment for an inflammatory bowel disease in a subject. In particular, using an indicator of epithelial absorption and metabolism the present disclosure provides method for determining the likelihood a subject is responsive or non-responsive to an inflammatory bowel disease therapeutic agent. The method includes providing a baseline measurement of a microvillus length in the small intestine of a subject, selecting a treatment for the subject according to a treatment criteria, and administering the treatment to the subject.
Resumen de: EP4632080A2
This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.
Resumen de: CN120775993A
The invention belongs to the field of molecular genetics, and particularly relates to an SNP (Single Nucleotide Polymorphism) molecular marker combination for genetic relationship identification of wuzhu cattle and application of the SNP molecular marker combination. The SNP marker combination is composed of 140 high-polymorphism SNP sites distributed on a plurality of chromosomes of a bovine whole genome, the average distance between the sites is reasonable, and the SNP marker combination has good genome coverage. The selected SNP site has high allele frequency (MAF), expected heterozygosity (He) and polymorphic information content (PIC), and the cumulative exclusion probability is 0.9999. King and Plink software are combined to deduce a genetic relationship coefficient (Kinship) and an IBD shared value (PIHAT) between samples, and a result shows that the marker combination can realize a genetic relationship recognition effect equivalent to that of whole genome SNP data in Wuzhu white cattle (grassland white cattle), and the scientificity and practicability of the marker combination are verified. The SNP molecular marker combination can be widely applied to the processes of germplasm resource management, pedigree correction and cattle breeding, and has good popularization prospects and economic benefits.
Resumen de: KR20250148382A
본 발명은 염증성 장질환(inflammatory bowel disease, IBD) 진단 및 치료를 위한 miRNA 바이오마커를 제공한다. 본 발명의 일 실시예에 따른 바이오마커는 염증성 장질환 진단용 조성물, 진단을 위한 정보 제공 방법, 염증성 장질환 예방 또는 치료용 약학 조성물, 염증성 장질환을 치료하는 방법 및 염증성 장질환 치료제의 스크리닝 방법에 활용될 수 있다.
Resumen de: CN120758646A
The invention discloses a tetraploid crassostrea gigas parent-child relationship identification method based on SNP sites, and belongs to the technical field of tetraploid crassostrea gigas molecular assisted breeding. The method for identifying the parent-child relationship of tetraploid crassostrea gigas comprises the following steps: (1) sequencing adductor muscles of tetraploid crassostrea gigas to be detected; (2) comparing the reference genome of the crassostrea gigas to obtain the genotype of the specified SNP site of the tetraploid crassostrea gigas; (3) calculating IBS and LOD of the to-be-detected parents and the to-be-detected offspring according to an SNP typing result; and (4) identifying the parent-child relationship between the to-be-detected parent and the filial generation by combining IBS and LOD. The SNP loci have the advantages that 1000 SNP loci for identifying the parent-child relationship of the tetraploid crassostrea gigas are disclosed for the first time, data support is provided for identifying the parent-child relationship of the tetraploid crassostrea gigas, a foundation is laid for developing a liquid phase chip for identifying the parent-child relationship of the tetraploid crassostrea gigas, and the SNP loci have good application prospects.
Resumen de: WO2025210486A1
Provided herein are methods for detecting inflammatory bowel disease (IBD) or risk of IBD in a canine based on the canine's gut microbiome. Also provided are methods for treating or preventing IBD in canines. Finally provided are probiotic compositions that are used in the methods of the present disclosure.
Resumen de: US2025313613A1
The present disclosure relates to: a method, a composition, and a method for producing the same for treating IBD using gastrointestinal contents or excretions modified with an IgA antibody; a method for obtaining an IgA antibody that restores the bacterial flora in the gastrointestinal tract of an IBD patient; a method, a composition, and a method for producing the same for modifying gastrointestinal contents or excretions of an IBD patient using an IgA antibody; and a method, a composition, and a method for producing the same for testing with the diagnostic pharmaceutical drug containing an IgA antibody in a patient treated with the IBD therapeutic agent containing gastrointestinal contents or excretions.
Resumen de: US2025313880A1
Methods and materials are disclosed for testing biomarkers in a subject suffering from inflammatory bowel disease (IBD) are described herein. Such detection can be useful for diagnosing and treating ulcerative colitis (UC) and Crohn's disease (CD), two forms of IBD that are otherwise difficult to distinguish. The method includes measuring the level of one or more of several biomarkers, including HD5 or MMP-7, which are expressed differentially in patents with UC and CD. A treatment may be based on the determination of whether the subject has ulcerative colitis or Crohn's disease.
Resumen de: US2025304705A1
The present disclosure relates to an orthogonal system comprising a first bi-specific polypeptide that comprises D-streptavidin or a variant thereof covalently linked to an antibody or antibody fragment and a second bi-specific polypeptide that comprises L-biotin covalently linked to a therapeutic or diagnostic agent. The disclosed systems can be useful in, for example, treating a disease or a condition (e.g., cancer, non-Hodgkin lymphoma, multiple sclerosis, Crohn's disease, rheumatoid arthritis, asthma, macular degeneration, psoriasis, Hodgkin lymphoma, paroxysmal nocturnal hemoglobinuria, X-linked hypophosphatemia). Also described are peptides and polypeptides useful in preparing the disclosed bi-specific polypeptides and methods of making same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Resumen de: US2025302891A1
Provided herein are methods for detecting inflammatory bowel disease (IBD) or risk of IBD in a canine based on the canine's gut microbiome. Also provided are methods for treating or preventing IBD in canines. Finally provided are probiotic compositions that are used in the methods of the present disclosure.
Resumen de: WO2025206567A1
The present invention provides a miRNA biomarker for diagnosing and treating inflammatory bowel disease (IBD). A biomarker according to one embodiment of the present invention can be utilized in a composition for diagnosing inflammatory bowel disease, a method for providing information for diagnosis, a pharmaceutical composition for preventing or treating inflammatory bowel disease, and a method for treating inflammatory bowel disease.
Resumen de: WO2025202626A1
The present techniques relate to a breath analysis device and a system for using such a breath analysis device. We also describe a method for using the breath analysis device. The breath analysis device comprises a filtering mechanism (which may also be termed a filter stack) for removing interferent chemicals to increase the accuracy of detection, identification and quantification of specific chemicals. Exhaled human breath comprises a multiplicity of vapour phase chemicals and the function of the filtering mechanism is removal, retardation and separation of chemicals other than the specific chemicals to be determined by the sensing element(s). Removal, retardation and separation of the chemicals other than those of interest reduces error by reducing cross sensitivities when using broadly selective sensors such as metal oxide semiconductors. One example use of the breath analysis device may be to enable users who suffer from digestive health problems, particularly irritable bowel syndrome (IBS) or small intestinal bacterial overgrowth (SIBO), to monitor symptoms based on detection of specific chemicals such as hydrogen and/or methane in their breath over time.
Resumen de: US2025305068A1
The present invention relates to a new biomarker of inflammatory bowel disease and its uses. The new biomarker is a ratio of Dialister spp. to Phascolarctobacterium spp. This biomarker can be used for diagnosis purpose of diseases or disorders associated with an intestinal dysbiosis, for stratifying patient population in a clinical trial, for selecting a subject that will benefit from a treatment, or for monitoring treatment response. The present invention further provides new therapeutic strategies.
Resumen de: AU2024236253A1
The present invention relates to an in vitro method for evaluating the state of intestinal permeability of a subject and, consequently, for the diagnosis of diseases or dysfunctions associated with intestinal hyper-permeability. More specifically, the procedure allows measuring using a common food component the amount of dietary antigen that can traverse a dysfunctional intestine. The procedure allows for the development of analytical products and processes within the framework of the medical devices industry.
Resumen de: CN120713972A
The invention discloses a traditional Chinese medicine compound for treating bowel stagnation and a preparation method, and relates to the technical field of traditional Chinese medicine preparation, the compound is prepared from the following raw materials in parts by mass: 12 parts of fried hawthorn, 12 parts of medicated leaven, 9 parts of ginger processed pinellia, 9 parts of poria cocos, 9 parts of pericarpium citri reticulatae, 9 parts of fructus forsythiae, 9 parts of radish seed, 9 parts of immature bitter orange, 9 parts of rhizoma cyperi, 6 parts of mangnolia officinalis, 9 parts of scutellaria baicalensis, 6 parts of coptis chinensis, 25 parts of raw atractylodes macrocephala koidz and 12 parts of rhizoma atractylodis. The medicated leaven in the traditional Chinese medicine compound is fried, so that the carried stale gas can be removed, the bitter taste generated in the subsequent decocting process can be reduced, thin-layer identification is performed on the fried hawthorn and the rhizoma atractylodis, the ratio can be calculated according to the distance from an original point to the center of a main spot and the distance from the original point to the front edge of a developing solvent, and the specific value can be calculated. And the property of the compound is judged, so that the decocted liquid medicine can be improved, and the gastrin level of a patient taking the liquid medicine can be effectively increased.
Resumen de: CN120719010A
The invention discloses an intestinal microbial marker related to irritable bowel syndrome, a product and application of the intestinal microbial marker, and belongs to the field of biological medicine. The invention relates to an enteric microbial marker, which is characterized in that the enteric microbial marker comprises one or more of Bacteroides multiforme, Clostridium concealum, Bacteroides ovale and Streptococcus sativus, and the enteric microbial marker comprises one or more of the following components: Bacteroides multiforme, Clostridium concealum, Bacteroides ovale and Streptococcus sativus, and the enteric microbial marker comprises one or more of Lactobacillus plantarum, Lactobacillus plantarum, Lactobacillus plantarum, Lactobacillus plantarum, Lactobacillus plantarum, Lactobacillus plantarum, Lactobacillus plantarum, Lactobacillus plantarum, Lactobacillus plantarum and Lactobacillus plantarum. The invention provides a kit which comprises a detection reagent for detecting the relative abundance of the intestinal microbial marker. The invention provides a product for diagnosing irritable bowel syndrome and a computer program product related to the irritable bowel syndrome. The product provided by the invention has good feasibility and accuracy, can effectively evaluate the risk of the irritable bowel syndrome, and provides a new tool for clinical diagnosis.
Nº publicación: CN120699897A 26/09/2025
Solicitante:
SOUTH CHINA UNIV OF TECHNOLOGY
SHENZHEN BAY LABORATORY
\u534E\u5357\u7406\u5DE5\u5927\u5B66,
\u6DF1\u5733\u6E7E\u5B9E\u9A8C\u5BA4
Resumen de: CN120699897A
The invention discloses a method for separating colonic lamina propria cells of mice with colitis and application of the method. According to the method, separation of the propria neutrophile granulocyte on the colon tissue with the complete length is tried for the first time, and the total time required by cell separation is effectively shortened through multiple digestion reagents with different compositions, so that apoptosis of the neutrophile granulocyte caused by long-time exposure of an intestinal sample is effectively avoided; the problems of low cell yield, poor activity and the like are solved, and a new thought is provided for separation of the neutrophile granulocytes.
BOPI
Sede Electrónica
